ResMed (RMD) Stock
Fundamentals
Recent news

ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
RMD

Is This the Right Time to Retain Resmed Stock in Your Portfolio?
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
RMD

ResMed Q4 Earnings Call Highlights
ResMed Q4 Earnings Call Highlights
RMD

RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y
RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y
RMD
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2026Earnings
The market is expecting earnings per share of $2.84 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
RMD

Is This the Right Time to Retain Resmed Stock in Your Portfolio?
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
RMD

ResMed Q4 Earnings Call Highlights
ResMed Q4 Earnings Call Highlights
RMD

RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y
RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y
RMD

ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat
ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat
RMD

ResMed (RMD) Q4 Earnings and Revenues Top Estimates
ResMed (RMD) Q4 Earnings and Revenues Top Estimates
RMD

What to Expect From These 2 MedTech Stocks This Earnings Season?
What to Expect From These 2 MedTech Stocks This Earnings Season?
RMD

Curious about ResMed (RMD) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Curious about ResMed (RMD) Q4 Performance? Explore Wall Street Estimates for Key Metrics
RMD

Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
RMD

Resmed's Q4 Earnings on Deck: What's in Store for the Stock?
Resmed's Q4 Earnings on Deck: What's in Store for the Stock?
RMD
About ResMed
Resmed pioneers innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Their digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. By enabling better care, they improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael J. Farrell BE, MBA, SM | CEO & Chairman | 1972 |
| Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScD | Founder, Chair Emeritus & Non-Executive Director | 1942 |
| Mr. Michael J. Rider | Chief Legal Officer & Secretary | 1958 |
| Mr. Brett A. Sandercock | Advisor | 1967 |
| Mr. Justin Leong | Chief Product Officer | 1978 |
| Mr. Aaron Bloomer | Chief Financial Officer | 1986 |
| Mr. Alastair Robertson | Chief Information Officer | — |
| Mr. Jim Ellis | Chief Compliance Officer | — |
| Ms. Yvonne-Katrin Pucknat | Chief Marketing Officer | 1976 |
| Ms. Vered Keisar | Chief People Officer | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
8 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -0.7 | +0.3 | -3.8 | +2.8 | ||||||||
| 2022 | -11.9 | +6.3 | -3.4 | -18.9 | +1.8 | +3.4 | +11.5 | -8.1 | -0.5 | -0.2 | +4.2 | -9.2 |
| 2023 | +9.2 | -7.0 | +2.3 | +9.9 | -10.1 | -0.1 | +3.6 | -29.2 | -7.1 | -3.1 | +7.2 | +7.8 |
| 2024 | +10.7 | -10.3 | +13.4 | +13.0 | -4.0 | -7.7 | +14.1 | +14.2 | -0.3 | +1.6 | +1.9 | -6.6 |
| 2025 | +3.4 | -2.9 | -4.0 | +6.4 | +3.5 | +5.7 | +6.1 | -1.7 | +1.0 | -8.8 | +2.8 | -3.0 |
| 2026 | +5.5 | +0.6 | -12.8 | -4.1 | -7.0 | +4.5 | +4.9 | +11.6 | -4.0 |
Corporate actions
Upcoming
No upcoming corporate actions for RMD



